Gold Nanoparticle‐Carrying T Cells for the Combined Immuno‐Photothermal Therapy

Author:

Kim HyeMi1,Baek Yujin2,Ha Taeyong3,Choi Doowon4,Lee Woo Jin3,Cho Yongbum4,Park Jeehun5,Kim Sungjee34,Doh Junsang256ORCID

Affiliation:

1. Center for Scientific Instrumentation Korea Basic Science Institute (KBSI) Daejeon 34133 South Korea

2. Department of Materials Science and Engineering Seoul National University Seoul 08826 South Korea

3. Department of Chemistry Pohang University of Science and Technology (POSTECH) Pohang 37673 South Korea

4. School of Interdisciplinary Bioscience and Bioengineering (I‐Bio) Pohang University of Science and Technology (POSTECH) Pohang 37673 South Korea

5. SOFT Foundry Institute Seoul National University Seoul 08826 South Korea

6. Research Institute of Advanced Materials (RIAM) Institute of Engineering Research BioMAX Institute Seoul National University Seoul 08826 South Korea

Abstract

AbstractCancer immunotherapy is a promising therapy to treat cancer patients with minimal toxicity, but only a small fraction of patients responded to it as a monotherapy. In this study, a strategy to boost therapeutic efficacy by combining an immunotherapy based on ex vivo expanded tumor‐reactive T cells is devised, or adoptive cell therapy (ACT), with photothermal therapy (PTT). Smart gold nanoparticles (sAuNPs), which aggregates to form gold nanoclusters in the cells, are loaded into T cells, and their photothermal effects within T cells are confirmed. When transferred into tumor‐bearing mice, large number of sAuNP‐carrying T cells successfully infiltrate into tumor tissues and exert anti‐tumor activity to suspend tumor growth, but over time tumor cells evade and regrow. Of note, ≈20% of injected doses of sAuNPs are deposited in tumor tissues, suggesting T cells are an efficient nanoparticle tumor delivery vehicle. When T cells no longer control tumor growth, PTT is performed to further eliminate tumors. In this manner, ACT and PTT are temporally coupled, and the combined immuno‐photothermal treatment demonstrated significantly greater therapeutic efficacy than the monotherapy.

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3